SAN
JOSE, Calif., Feb. 24,
2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"
or the "Company") (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer, today is pleased to
announce that its pioneering CAR-T therapy for ovarian cancer,
developed in collaboration with Moffitt Cancer Center ("Moffitt"),
was prominently featured in Breaking Cancer News in an article
titled "Navigating Uncharted Territory: CAR-T for Ovarian
Cancer."
The article highlights the groundbreaking clinical trial led by
Dr. Robert Wenham, Chairman of the
Department of Gynecologic Oncology at Moffitt Cancer Center, and
Dr. Monica Avila, a leading
gynecologic oncologist at Moffitt. The trial explores the use of
chimeric antigen receptor-T cell (CAR-T) therapy to treat ovarian
cancer, a disease with historically limited treatment options for
advanced-stage patients.
The CAR-T therapy being studied in this trial, exclusively
licensed to Anixa from The Wistar Institute, and developed through
a partnership between Anixa and Moffitt, is designed to target the
follicle-stimulating hormone receptor (FSHR), a protein uniquely
expressed on ovarian cancer cells. This novel approach has the
potential to revolutionize the treatment of ovarian cancer by
leveraging the body's immune system to directly attack tumors.
Dr. Amit Kumar, Chairman and CEO
of Anixa Biosciences, commented, "We are honored to see our work
recognized in Breaking Cancer News and to witness the promising
impact this CAR-T therapy is having on patients. Our partnership
with Moffitt Cancer Center exemplifies our commitment to developing
novel and targeted immunotherapies that could transform the
standard of care for some of the most challenging cancers,
including ovarian cancer."
The article also highlights the potential expansion of the study
to evaluate repeat dosing, given Gallagher's response, and explores
the broader implications of CAR-T therapy for solid tumors—an area
of intense research and high unmet medical need.
The full article can be accessed here:
https://breakingcancernews.com/2025/02/18/navigating-uncharted-territory-car-t-for-ovarian-cancer/.
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio
consists of an ovarian cancer immunotherapy program
being developed in collaboration with Moffitt Cancer
Center, which uses a novel type of CAR-T, known as
chimeric endocrine receptor-T cell
(CER-T) technology. The Company's vaccine portfolio
includes vaccines being developed in collaboration with Cleveland
Clinic to treat and prevent breast cancer and ovarian cancer, as
well as additional cancer vaccines to address many intractable
cancers, including high incidence malignancies in lung, colon, and
prostate. These vaccine technologies focus on immunizing against
"retired" proteins that have been found to be expressed in certain
forms of cancer. Anixa's business model of partnering
with world-renowned research institutions on all stages of
development allows the Company to continually examine emerging
technologies in complementary fields for further development and
commercialization. To learn more, visit
www.anixa.com or follow Anixa on
Twitter, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
Statements that are not
historical fact may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are not statements of historical
facts, but rather reflect Anixa's current expectations concerning
future events and results. We generally use the words "believes,"
"expects," "intends," "plans," "anticipates," "likely," "will" and
similar expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contact:
Mike
Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-featured-in-breaking-cancer-news-article-on-novel-car-t-therapy-for-ovarian-cancer-302383018.html
SOURCE Anixa Biosciences, Inc.
